New Jersey Drug Utilization Review Board
Virtual Platform
October 21, 2026

https://nj.gov/humanservices/dmahs/public-advisory/durb/

AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. July 15, 2026, Meeting Packet
https://www.nj.gov/humanservices/dmahs/documents/boards/durb/meeting/DURB_Meeting_Docs_7-15-26.pdf

IV. Review of meeting transcript for July 15, 2026, Meeting
https://www.nj.gov/humanservices/dmahs/documents/boards/durb/agendas/10-2026/Transcript_NJDURB_Meeting_July_2026.pdf

V. Review of draft meeting summary for July 15, 2026, Meeting (pages 3-6)

VI. Secretary's report (page 7)

VII. Old Business
- A. Utilization Trends of GLP-1/GIP Agonists (pages 8-9)
- B. Utilization Trends of SGLT-2 Inhibitors (pages 10-11)
- C. Proposed Addendum to Protocol for Gattex® (pages 12-13)

VIII. New Business
- A. Proposed Addendum to Protocol for Imcivree® (pages 14-16)
- B. Proposed Protocol for Zelsuvmi™ and Ycanth® (pages 17-18)
- C. Proposed Protocol for Olumiant® (pages 19-20)
- D. Proposed Protocol for Otezla®/Otezla XR™ (pages 21-23)

IX. A. Informational Highlights/Reports

1. Gainwell Technologies/NJ MCO 2nd Quarter 2026 Prior Authorization Report (page 24)
2. Summary of DURB Action Items (pages 25-28)
3. DHS/DOH Pharmacy Programs Top Drugs Report/Physicians Administered Drugs Report (by amount paid and by category):

   FFS top drugs:
   http://www.state.nj.us/humanservices/dmahs/documents/boards/durb/agendas/10-2026/FFS_Top_Drugs_Report_by_07-2026.pdf

   MCO top drugs:
   http://www.state.nj.us/humanservices/dmahs/documents/boards/durb/agendas/10-2026/MCO_Top_Drugs_Report_by_07-2026.pdf

   FFS top drugs by category:
   http://www.state.nj.us/humanservices/dmahs/documents/boards/durb/agendas/10-2026/FFS_Top_Drugs_by_Category_07-2026.pdf

   MCO top drugs by category:
   http://www.state.nj.us/humanservices/dmahs/documents/boards/durb/agendas/10-2026/MCO_Top_Drugs_by_Category_by_07-2026.pdf

   FFS antiviral drugs:
   http://www.state.nj.us/humanservices/dmahs/documents/boards/durb/agendas/10-2026/FFS_Antiviral_Drugs_by_07-2026.pdf

B. Recent Updates

American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults with Type 2 Diabetes – 2026 Update
https://www.endocrinepractice.org/article/S1530-891X(26)00022-4/fulltext#fig2

2026 American College of Rheumatology (ACR) Juvenile Idiopathic Arthritis (JIA) Guidelines
https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/blt4e307b8933591fa5/jia-guidelines-summary-2026.pdf

Generic and Biosimilar Prescribing in Children and Adolescents: Policy Statement
https://publications.aap.org/pediatrics/article/157/6/e2026077027/207622/Generic-and-Biosimilar-Prescribing-in-Children-and?autologincheck=redirected